B-Type Natriuretic Peptide

BNP

BNP, Brain Type Natriuretic Peptide

EDTA Pink top (PCM)
Plasma

• Samples should be tested as soon as possible after collection. 
• Blood and plasma specimens may be stored at room temperature for up to 7 hours after collection.
• Plasma specimens may be stored refrigerated at 2 - 8^o C for up to 24 hours after collection. Plasma specimen may be stored frozen at - 20^o C in a non-defrosting freezer for long term storage. Thaw the sample only once; and, allow the sample to come to room temperature for 30 minutes prior to testing.

Marked Hemolysis

24x7

24x7

Reference Range: 0-100 pg/mL


BNP correlates with the severity of congestive heart failure. The approximate mean values obtained in patients with NYHA severity categories are:

    NYHA Functional                   Male                    Female
       Class                             BNP (pg/ml)           BNP (pg/ml)

    Class I   -                              145.5                    148.5
    Class II  -                              306.4                    384.5
    Class III -                               557.4                   613.8
    Class IV  -                              927.7                   858.4

Congestive heart failure (CHF) occurs when the heart cannot deliver a sufficient amount of blood to the body. This condition can occur at any age but is most prevalent in an aged population. Symptoms of CHF include shortness of breath, fluid retention and respiratory distress. These symptoms are often vague and nonspecific for detecting early stages of CHF. B-type natriuretic peptide (BNP) is a member of a class of hormones that regulate blood pressure. The heart is the main source of circulating BNP in humans. The molecule is released into the blood in response to increased heart pressure. Various studies have demonstrated that increased levels of circulating BNP are found in early stages of CHF. The level of BNP in the blood continues to increase as the CHF disease advances. The Alere Triage BNP test offers an objective, noninvasive measurement for assessing patients for CHF and risk stratification in patients with acute coronary syndromes (ACS).

Use:

• as an aid in the diagnosis of congestive heart failure (also referred to as heart failure)


• as an aid in the assessment of severity of congestive heart failure


• for the risk stratification of patients with acute coronary syndromes


•  for the risk stratification of patients with heart failure